Align Technology (ALGN)
(Delayed Data from NSDQ)
$212.15 USD
+1.37 (0.65%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $211.69 -0.46 (-0.22%) 6:40 PM ET
4-Sell of 5 4
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$212.15 USD
+1.37 (0.65%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $211.69 -0.46 (-0.22%) 6:40 PM ET
4-Sell of 5 4
C Value B Growth C Momentum C VGM
Zacks News
CONMED (CNMD) Earnings Meet, Revenues Beat Estimates in Q2
by Zacks Equity Research
CONMED's (CNMD) strong global performance was a key highlight in the second quarter of 2017.
LabCorp (LH) Beats on Q2 Earnings and Sales, Guidance Up
by Zacks Equity Research
LabCorp's (LH) dull Covance Drug Development performance is offset by solid growth in Diagnostics. Increased guidance raises hope.
Med-Products' Q2 Earnings Roster for Jul 27: ALGN, BSX & More
by Zacks Equity Research
The ongoing conflict related to healthcare policy implementation in the U.S. might get reflected in the Q2 results of these companies.
Chemed (CHE) Q2 Earnings & Revenues Rise Y/Y, View Revised
by Zacks Equity Research
Chemed (CHE) rides high on Roto-Rooter in second-quarter 2017. An encouraging bottom-line projection raises hopes.
Should You Buy Align Technology (ALGN) Ahead of Earnings?
by Zacks Equity Research
Align Technology (ALGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.
Express Scripts (ESRX) Earnings Top in Q2, FY17 View Up
by Zacks Equity Research
Express Scripts (ESRX) perform well in the second quarter on the back of operational cost improvement backed by focus on home delivery and specialty services.
What to Expect from International Paper (IP) in Q2 Earnings?
by Zacks Equity Research
Fluctuations in actual equity market returns, changes in general interest rates are likely to hurt International Paper (IP) in Q2 earnings.
VASCO (VDSI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Vasco's (VDSI) focus on generating high operating margins, backed by continuous investments and a shift in the product mix with higher gross-margin products, is likely to boost its Q2 earnings.
PetMed Express (PETS) Tops Earnings, Revenue Estimates in Q1
by Zacks Equity Research
PetMed (PETS) initiated fiscal 2018 with better-than-expected results in the first quarter, beating both earnings and revenues.
Ecolab (ECL) to Report Q2 Earnings: Will It Pull a Surprise?
by Zacks Equity Research
Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Ecolab's (ECL) growth in the second quarter.
Can Cerner (CERN) Deliver a Beat this Earnings Season?
by Zacks Equity Research
We believe Cerner's (CERN) strong sales performance, solid portfolio and strategic initiatives have positioned it for stellar growth.
What to Expect from Anthem (ANTM) this Earnings Season?
by Zacks Equity Research
Anthem's (ANTM) second-quarter earnings are likely to be supported by robust medical enrollment. However, rising level of SG&A expenses might put pressure on the bottom line.
Centene (CNC) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Centene's (CNC) second-quarter earnings are likely to be driven by Health Net buyout. However, surging level of SG&A expenses might put pressure on the bottom line.
Universal Health (UHS) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Universal Health's (UHS) second-quarter earnings are likely to be boosted by solid revenue growth. However, increasing cost of debt might hurt the bottom line.
Will Stryker (SYK) Deliver a Beat this Earnings Season?
by Zacks Equity Research
The growing adoption of Stryker's (SYK) MAKO robots is expected to drive second-quarter 2017 sales in the orthopedic and reconstructive surgery market.
Abbott Labs (ABT) Beats on Q2 Earnings and Sales, View Up
by Zacks Equity Research
Abbott Labs' (ABT) Q2 performance was strong on solid EPD and Medical Device growth. The stock's guidance for 2017 has also been raised.
What's in Store for Express Scripts (ESRX) in Q2 Earnings?
by Zacks Equity Research
Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Express Scripts' (ESRX) growth in the second quarter.
Align Technology (ALGN) Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
Align Technology (ALGN) might ride high in Q2 banking on growth in the Invisalign space.
Quest Diagnostics Closes Deal to Acquire 2 Labs in Texas
by Zacks Equity Research
Quest Diagnostics (DGX) acquires Med Fusion and Clear Point lab businesses to grow in oncology space.
Is a Surprise in Store for CR Bard (BCR) in Q2 Earnings?
by Zacks Equity Research
Growing adoption of the company's flagship Lutonix drug coated-balloon is expected to benefit C.R. Bard's (BCR) performance in the second quarter.
GNC Holdings (GNC) Q2 Earnings: Disappointment in the Cards?
by Zacks Equity Research
We do not expect GNC Holdings (GNC) to beat estimates in Q2 earnings on account of a tough competitive landscape and currency headwinds.
Edwards Lifesciences (EW) Q2 Earnings: A Surprise in Store?
by Zacks Equity Research
Edwards Lifesciences (EW) will likely ride high in Q2 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve space.
Can Quest Diagnostics (DGX) Pull a Surprise in Q2 Earnings?
by Zacks Equity Research
Weak revenue per requisition performance and reimbursement pressure might dampen Quest Diagnostics' (DGX) benefits from esoteric testing business, infectious disease testing and prescription drug monitoring business growth.
Align Technology Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Share price of San Jose, CA-based Align Technology, Inc. (ALGN) reached a new 52-week high of $157.86 on Jul 17, eventually closing a bit lower at $156.21.
Medtronic InterStim System Shows Five-Year Positive Results
by Zacks Equity Research
Medtronic plc (MDT) has announced that its InterStim system provides sustained long-term efficacy and improved quality of life for overactive bladder (OAB) patients at the end of five years.